## Programme of the Conference

08:30 - 09:00	Registration and coffee
09:00 - 09:10	Welcome
	Christine E. Hallgreen, Associate Professor and Director CORS

Session 1: Im	plementation of RWE in regulatory decision making	
Chair: Christine E. Hallgreen, Associate Professor and Director CORS		
09:10 -09:35	PHAIR: Pharmacovigilance by Al Real-time Analysis.	
	Jesper Kjær, Director of the Danish Medicines Agency's Data Analytics	
	Centre and co-chair at EMA/HMA Big Data Steering Group	
09:35 – 10:00	Clinical Evidence 2030	
	Peter Arlett, Head of the EMA Data Analytics and Methods Taskforce	
10:00 – 10:30	Coffee break	
10:30 – 11:00	(Online)	
	RWE in regulatory science	
	Britta Hänisch, Head of the research division, Federal Institute for Drugs and	
	Medical Devices (BfArM), Bonn	
11:00 - 11:30	(Online)	
	Beginning convergence on conducting RWE studies to estimate treatment	
	effects	
	Sebastian Schneeweiss, Chief, Division of Pharmacoepidemiology and	
	Pharmacoeconomics, Harvard Medical School; Professor in Epidemiology,	
	Harvard T.H. Chan School of Public Health	
11:30 – 12:00	Panel discussion and Q & A	
12:00 -13:00	Lunch and poster exhibition of Regulatory Science PhD and Master	
	projects	

Session 2: Examples of RWE use			
Chair: Marieke De Bruin, Professor Utrecht University, Scientific Director of the Utrecht			
Centre for Pharmaceutical Policy and Regulation			
13:00 – 13:30 Examples of stepped wedge and cluster randomised clinical trials - from			
13.00 – 13.30			
	the perspective of the clinical researcher.		
	Pernille Brok Nielsen, Physician and PhD student at Herlev and Gentofte		
	Hospital, Pragmatic trial experience		
13:30 – 14:00	Expanding the use of RWE across the product life cycle		
	Alison Cave, Chief Safety Officer at Medicines and Healthcare products		
	Regulatory Agency (MHRA)		
14:00 – 14:30	Regulatory use of RWE and Industry: the need for T-shaped RWD and X-		
	shaped methods		
	<b>Nigel Hughes</b> , Scientific Director of the Observational Health Data Analytics		
	at Janssen, Project Lead for the IMI2 European Health Data & Evidence		
	Network (EHDEN)		
14:30 – 15:00	Coffee break		

Session 3: Methodologies in RWE		
Chair: Theis Lange, Head of Department, Professor Department of Public Health UCPH		
15:00 – 15:30	A Bayesian perspective on real-world data analysis	
	Chris Holmes, Programme Director for Health and Medical Sciences at The	
	Alan Turing Institute and Professor of Biostatistics at the University of	
	Oxford	
15:30 – 16:00	Bounding RWE and a potential new causal pipeline	
	Erin Evelyn Gabriel, Associate professor in Biostatistics at UCPH, Principal	
	Researcher and Docent in Biostatistics at Karolinska Institutet, and Affiliate	
	Researcher at the National Institute of Allergy and Infectious Diseases (NIH)	
16:00 – 16:20	Panel discussion and Q & A	
16:20 – 16:30	Closing remarks	
	<b>Nikolai B Brun,</b> Affiliate Professor CORS, Chief Medical Officer Affibody AB	